Abstract | BACKGROUND: PATIENTS AND METHODS: Fifteen consecutive patients with advanced HCC were included in the study. Patients were evaluated for survival, quality of life, liver function, tumor mass, toxicity related to the treatment and retinoid receptors in liver biopsies. RESULTS: The median survival of our patients was 22 months. Pain and asthenia were improved in the majority of patients. Every patient with baseline elevated liver enzymes showed an improvement in liver function. RAR-alpha, RXR-alpha, RAR-beta and RAR-gamma receptors were demonstrated in 100%, 73%, 47% and 40%, respectively. CONCLUSION:
|
Authors | Carlo Clerici, Danilo Castellani, Giuseppe Russo, Stefano Fiorucci, Giuseppe Sabatino, Vittorio Giuliano, Giorgio Gentili, Olivia Morelli, Patrizia Raffo, Monia Baldoni, Antonio Morelli, Salvatore Toma |
Journal | Anticancer research
(Anticancer Res)
2004 Mar-Apr
Vol. 24
Issue 2C
Pg. 1255-60
ISSN: 0250-7005 [Print] Greece |
PMID | 15154656
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Tamoxifen
- Vitamin E
- Tretinoin
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy)
- Female
- Humans
- Liver Neoplasms
(drug therapy)
- Male
- Middle Aged
- Pilot Projects
- Tamoxifen
(administration & dosage, adverse effects)
- Tretinoin
(administration & dosage, adverse effects)
- Vitamin E
(administration & dosage, adverse effects)
|